HAC (Russian)
RSCI (Russian)
EBSCO
DOI (USA)
Ulrichsweb (Ulrich’s Periodicals Directory)
Scientific Indexing Services

Pelvic inflammatory diseases and their therapy in outpatient settings

DOI: https://doi.org/10.29296/25877305-2022-08-03
Issue: 
8
Year: 
2022

Professor V. Skvortsov, MD; E. Skvortsova; Associate Professor I. Statsenko, Candidate of Medical Sciences; O. Razvalyaeva; K. Durnoglazova
Volgograd State Medical University, Ministry of Health of Russia

Pelvic inflammatory diseases (PIDs) are a collective term embracing infectious and inflammatory diseases of the upper female genital tract involving the uterine (fallopian) tubes, ovaries, and surrounding tissues. The paper considers the classification, etiology, and pathogenesis of PID, describes the clinical presentation of the disease, and also provides the main methods of diagnosis and drug therapy.

Keywords: 
gynecology
pelvic inflammatory diseases
antibiotic therapy



References: 
  1. Bezbakh I.V. Primenenie strukturno-rezonansnoi terapii v vosstanovitel’nom lechenii bol’nykh khronicheskim sal’pingoofortom. Zhurnal Rossiiskogo obshchestva akusherov-ginekologov. 2006; 3: 26–8 (in Russ.).
  2. Medvedev B.I. et al. Vospalitel’nye zabolevaniya matki i pridatkov. Chelyabinsk, 2001; 278 р. (in Russ.).
  3. Strizhakov A.N. et al. Genital’nye infektsii. M.: ID «Dinastiya», 2003; 134 s. (in Russ.).
  4. Krasnopolsky V.I. et al. Pyoseptic complications in obstetrics and gynecology: pathogenesis, diagnosis, and treatment policy. Russian Bulletin of Obstetrician-Gynecologist. 2007; 7 (1): 63–8 (in Russ.).
  5. Jaiyeoba O., Lazenby G., Soper D.E. Recommendations and rationalefor the treatment of pelvic inflammatory disease. Obstetrics and Gynecology. News, Opinions, Training. 2013; 1: 43–54 (in Russ.).
  6. DeCherney A.H., Nathan L. Obstetric & Gynecologic. M.: MED-press-inform, 2009; s. 216–7 (in Russ.).
  7. Konovalova M.V. et al. Niskhodyashchee rasprostranenie infektsii posle meditsinskogo aborta pri khronicheskikh vospalitel’nykh ginekologicheskikh zabolevaniyakh. Evraziiskoe Nauchnoe Ob’edinenie. 2020; 11-3 (69): 185–8 (in Russ.).
  8. Pestrikova T.Yu., Yurasov I.V., Yurasova E.A. et al. Personalized approach to management of patients with chronic pelvic diseases at the pre-gravida stage. Far Eastern Medical Journal. 2015; 3: 36–40 (in Russ.).
  9. Sauleva T. Sovremennye vzglyady na etiologiyu, patogenez, diagnostiku i lechenie bakterial’nogo vaginoza kak zabolevaniya, peredavaemogo polovym putem. Bicnik mor’koi meditsini. 2000; 3: 28–32 (in Russ.).
  10. Davis R., Bryson H.M. Levofloxacin: a review of its antibacterial activity, farmacokinetics and therapeutic efficacy. Drugs. 1994; 47 (4): 677–700. DOI: 10.2165/00003495-199447040-00008
  11. Cooper I., Isbell D.J., Kruszinsky J.A. et al. Comparative in vitro activity of Levofloxacin and FK037 to other agents against 10,040 fresh clinical isolates. Int J Antimicrob Agents. 1996; 6 (4): 201–11. DOI: 10.1016/0924-8579(95)00039-9
  12. DeAbate C.A., Russel M., McElvaine P. et al. Safety and efficacy of levofloxacin versus cefuroxime axetil in acute bacterial exacerbation of chronic bronhitis. Respir Care. 1997; 42 (2): 206–13.
  13. Guay D.R.P. Implications of quinolones pharmacocinetic drag interactions. Hosp Pharm. 1997; 32: 677–90.
  14. Fish D.N. Fluoroquinolones adverse effects and drag interactions. Pharmacotherapy. 2002; 21 (10 pt 2): 253S–272S. DOI: 10.1592/phco.21.16.253s.33993
  15. Lipsky B.A., Baker C.A. Fluoroquinolones toxicity profiles: a review focusing on newer agents. Clin Infect Dis. 1999; 28: 352–64. DOI: 10.1086/515104